Immunai - Reprogramming immunity

Noam Solomon, PhD

CEO & Co-Founder

Noam Solomon is the CEO and co-founder at Immunai, the first company set to reprogram the immune system for better detection, diagnosis, and treatment of disease, and discovery of novel therapeutics.

Prior to co-founding Immunai, Noam had a dual career in both the industry and academia. Noam has a double Ph.D., in Math and Computer Science and served as a post-doctoral researcher in the Mathematics department at the Massachusetts Institute of Technology, and in the Center of Mathematical Sciences and Applications at Harvard University.

Noam also worked as an algorithms developer and a data scientist, consultant, and head of data science in several hi-tech companies in Israel.

Tali Raveh-Sadka, PhD

VP, Computational R&D

Tali Raveh-Sadka, Immunai’s VP of Computational Biology, holds a PhD in Computational Biology from the Weizmann Institute of Science and completed her post doc at the University of California, Berkeley. Prior to joining Immunai, Tali was the Director of Research at DayTwo.

Tali lives in Israel with her husband, father-in-law, two kids, and three hamsters.

Sen Zhang

VP, Product

Sen Zhang, Immunai’s Vice President of Product, joined Immunai in January 2020 as its first product hire.

Prior to Immunai, Sen spent a decade leading a variety of product and business initiatives at Two Sigma Investments, Flatiron Health, and Palantir Technologies. Sen started his career as a consultant at Oliver Wyman, working on a variety of projects in the financial services industry.

Sen earned BAs in Biology and Economics at Dartmouth College. He lives in New York City with his wife.

Adeeb Rahman, PhD

VP, Single Cell Immunology

Adeeb Rahman, Immunai’s Senior Director of Single-Cell Immunology, joined Immunai after nearly a decade at the Icahn School of Medicine at Mount Sinai in a variety of roles.

Most recently, Adeeb was an Associate Professor in the Department of Genetics and Genomic Sciences, a member of the Precision Immunology Institute and Tisch Cancer Institute and served as the Director of Technology Development for the Human Immune Monitoring Center.

In that role, he led a team of wet bench and computational scientists focused on developing and optimizing high-dimensional cytometry and multi-modal single-cell immunological assays, and collaboratively applying them across a wide range of basic, translational and clinical research projects.

His lab also served as a central hub for several multi-institutional academic and industry collaborations including the NIH Human Immunology Project Consortium (HIPC), the CZI Seed Networks for the Human Cell Atlas (HCA), the NCI Cancer Immune Monitoring and Analysis Centers (CIMAC) and the Partnership for Accelerating Cancer Therapies (PACT).

Adeeb earned his Bachelor of Science in Biology from Brown University and his PhD in Immunology from the University of Pennsylvania School of Medicine and completed postdoctoral fellowships at the University of North Carolina, Chapel Hill and the Icahn School of Medicine at Mt. Sinai. He lives in New York City with his wife and two daughters.

Evan Zisholtz

VP, Corporate Development

Evan is the Vice President of Corporate Development for Immunai. He oversees Business Development, M&A and Strategy. Prior to Immunai, Evan was at Lonza where he supported M&A and Corporate Strategy. Evan began his career as an attorney in private practice in New York. Evan holds a JD from New York University School of Law.

Roy Cohen

VP, Finance

Roy is the Vice President of Finance for Immunai. He oversees Finance, Legal and long-term strategic planning. Roy is a Finance executive with over 17 year of financial management in public traded tech companies. He brings track record in supporting scaling company growth, implementing major processes and tools through business-related strategy execution and building long term financial strategy. Roy joined Immunai from Kornit Digital where he started as Director of FP&A, overseeing financial planning, C&B & Risk management, and was promoted to VP Finance and later on as VP Of aftermarket business where he was in charge on $140m business. Roy holds a bachelor’s degree in Economic & Management and a MBA from Bar-Ilan University

Elisha Nathan

VP, Strategic Alliances

Elisha Nathan, Immunai’s VP of Strategic alliances, holds a PhD in Molecular Biology from the Weizmann Institute of Science and an MBA from Bar-Ilan University. Prior to joining Immunai, Elisha was the VP of Strategic alliances at CytoReason and served as the Director of Business Development in Evogene (Nasdaq: EVGN) and Protalix (NYSE :PLX)

Philip Zimmermann

VP, Business Development Europe

Philip Zimmermann, VP Business Development Europe, joined Immunai in 2021 as part of the acquisition of Nebion by Immunai.

Philip co-founded and led Nebion as CEO for thirteen years, with his main roles in business development for the SaaS product GENEVESTIGATOR and accompanying curation services. He helped establish Nebion as a prime service provider for high quality curated data and analysis tools. Prior to that, Philip earned his PhD at ETH Zurich, where he spent a postdoc and three years as team leader with a focus on systems biology and bioinformatics.

Galit Yahalom

VP, Operations

Galit Yahalom, Immuani’s VP of operations, joined Immunai after an extensive career in the biotechnology industry. Prior to joining Immunai she served as VP of clinical, laboratory and regulatory affairs of Oncohost, COO of Eventus Dx, and a consultant to the industry.

Galit holds a PhD in molecular biology from the Weizmann institute of Science, lives in Modiin with her husband and two kids.

Luis Voloch

Co-Founder

Luis Voloch is one of Immunai’s two co-founders, and served as the Chief Technology Officer from its founding until the end of 2022, where he also served in the Board of Directors and managed the Scientific Advisory Board.

Before co-founding Immunai, Luis served as Head of Data Science and Machine Learning and worked on a variety of Machine Learning efforts at Palantir and other companies, where he has worked on and led various AI, genomics, and software efforts. He also won the Best Thesis Award among all PhD-track students in MIT. At various times in Immunai, he managed its software, machine learning, computational biology, immunology, project management, and genomics teams.

Danny Wells, PhD

Scientific Co-Founder

Danny Wells is a scientific co-founder at Immunai, previously serving as the Senior Vice President of Strategic Research. Danny joined the founding team of Immunai during his time as an investigator at the Parker Institute for Cancer Immunotherapy, where he was the founding principal data scientist and led research efforts in genomics and reverse translational medicine.

Danny has co-authored dozens of research articles around the intersection of (single-cell) genomics and cancer immunotherapy that have collectively been cited thousands of times, including papers published in Nature, Cell, and Nature Medicine.

Before joining the Parker Institute, Danny completed a postdoctoral fellowship in evolutionary biology at the University of California, Berkeley, his PhD in Computational Biology and Applied Mathematics at Northwestern University, where he was an NSF Graduate Research Fellow, and a BA in Mathematics from Carleton College where received the Galovich Prize for accomplishment in undergraduate mathematics research.

Danny lives in Berkeley, CA with his wife and two sons, and enjoys spending time with them cooking and hiking in the hills around their home.

Ansuman Satpathy, MD, PhD

Scientific Co-Founder

Dr. Ansuman Satpathy M.D., Ph.D. is an Assistant Professor in the Department of Pathology at Stanford University School of Medicine and a Scientific Co-Founder of Immunai. He is an investigator in the Gladstone-UCSF Institute of Genomic Immunology, the Parker Institute for Cancer Immunotherapy, and the Stanford Cancer Institute.

Dr. Satpathy has pioneered the development and use of high-throughput genome sequencing technologies to study cancer immunology. His work has led to fundamental insights into how T cells – the cancer killing immune cell in the body – recognize and respond to cancer antigens and various forms of cancer immunotherapy. Dr. Satpathy’s honors include the Pew-Stewart Scholar Award in Cancer Research, the Lloyd J. Old STAR Award from the Cancer Research Institute, the Career Award for Medical Scientists from the Burroughs Wellcome Fund, and the Michelson Prize in Human Immunology.

Dr. Satpathy completed an M.D. and Ph.D. in immunology at Washington University in St. Louis, clinical residency in pathology at Stanford Hospital and Clinics, and postdoctoral training in genetics at Stanford University.

Dan Littman, MD, PhD

Scientific Co-Founder

Dr. Littman is a Howard Hughes Medical Institute Investigator and the Helen L. and Martin S. Kimmel Professor of Molecular Immunology and Professor of Pathology and Microbiology at the New York University (NYU) School of Medicine.

Dr. Littman is a Fellow of the American Academy of Arts and Sciences and is a Member of the National Academy of Sciences and of the National Academy of Medicine. He is recipient of the New York City Mayor’s Award for Excellence in Science and Technology, the AAI-Invitrogen Meritorious Career Award, the Ross Prize in Molecular Medicine, the William B. Coley Award from the Cancer Research Institute, and the Vilcek Prize in Biomedical Sciences.

Dr. Littman has made numerous groundbreaking discoveries in the fields of virology and immunology, including identification and isolation of receptors required for human immunodeficiency virus (HIV) entry, molecular mechanisms of immune cells that mediate autoimmunity and the role of specific members of the gut microbiota in T-cell differentiation.

Robert S. Langer, PhD

Dr. Robert Langer serves on Immunai’s Board of Directors. Bob is 1 of 12 Institute Professors at the Massachusetts Institute of Technology (MIT); being an Institute Professor is the highest honor that can be awarded to a faculty member. Bob is also a faculty member of the Harvard-MIT Program in Health Sciences and Technology and the Koch Institute for Integrative Cancer Research.

Langer holds over 1,400 granted or pending patents and is one of the world’s most highly cited researchers. His h-index is 301 with over 365,000+ citations. He is widely recognized in biotechnology, especially in the fields of drug delivery systems and tissue engineering. Bob is also a prolific entrepreneur and participated in the founding of over 40 biotechnology companies, including Moderna. Langer’s research laboratory at MIT is the largest biomedical engineering lab in the world; maintaining over $10 million in annual grants and over 100 researchers. He has been awarded numerous leading prizes in recognition of his work.

Mark Jacobstein

Mark Jacobstein came to Immunai by way of Guardant Health, where he spent four years as the Chief User Engagement Officer.

Prior to this Mark was CEO of iSkoot until its acquisition by Qualcomm. Mark was also an EVP at loopt (sold to GreenDot) and the co-founding President of Sequoia-backed Digital Chocolate, a pioneer in mobile games.

In 1994 Mark founded Small World Sports, the world’s first online fantasy sports business, and served as CEO until he sold the business in 2002. Mark also co-founded Small World Software, which he sold to iXL, where he served as SVP of business development through their 1998 IPO. 

Mark earned his BA from Harvard University, where he concentrated in Computer Science, and lives in Stanford, CA with his family.

Regina Barzilay, PhD

Dr. Regina Barzilay is a School of Engineering Distinguished Professor for AI and Health in the Department of Electrical Engineering and Computer Science and a member of the Computer Science and Artificial Intelligence Laboratory at the Massachusetts Institute of Technology. She is an AI faculty lead for Jameel Clinic, an MIT center for Machine Learning in Health.

Her research interests are in natural language processing and applications of deep learning to chemistry and oncology. She is a recipient of various awards including the NSF Career Award, the MIT Technology Review TR-35 Award, Microsoft Faculty Fellowship and several Best Paper Awards at NAACL and ACL. In 2017, she received a MacArthur fellowship, an ACL fellowship and an AAAI fellowship. In 2020, she was awarded the Squirrel AI Award for Artificial Intelligence for the Benefit of Humanity.

She received her PhD in Computer Science from Columbia University, and spent a year as a postdoc at Cornell University. Prof. Barzilay received her undergraduate degree from Ben-Gurion University of the Negev, Israel.

Stanley Frankel, MD

Dr. Stanley R. Frankel (M.D.) is Adjunct Professor of Medicine at the Division of Hematology/Oncology at Columbia University’s Vagelos College of Physicians and Surgeons, and Consultant to the world’s most innovative companies developing immuno-oncology and cellular therapies, drugs and compounds. Dr. Frankel sits on the Board of Directors and the Science and Technology Committee of Precision BioSciences, Inc. where he supports the development, approval and commercial deployment of advanced gene correction therapies.

Dr. Frankel is a leading academic and industry expert in the research, clinical development, and commercialization of cellular therapies. He has led clinical development programs for multiple FDA-approved drugs to treat hematologic malignancies including acute lymphoblastic leukemia, multiple myeloma, and lymphoma.

Dr. Frankel has held the highest executive and leadership positions at Bristol-Myers Squibb (BMS), Celgene, Merck, AMGEN, Hoffmann-LA Roche, and others; he has also served on steering/development committees with JW Therapeutics, Jounce Therapeutics, Astra-Zeneca/Medimmune, Juno Therapeutics, and BeiGene.

Dr. Frankel received a B.A. in Applied Sciences, Biomechanics from Harvard College and an M.D. from Northwestern University, and has been a board-certified licensed physician since 1986. He completed his residency at Mount Sinai Hospital and his fellowship at Memorial Sloan Kettering Cancer Center, where he was Chief Fellow. Frankel has held academic and clinical appointments at Roswell Park Cancer Institute, Georgetown University, and the University of Maryland.

Caroline Uhler, PhD

Dr. Caroline Uhler co-directs the Eric and Wendy Schmidt Center at the Broad Institute. She is also Associate Professor in the Department of Electrical Engineering and Computer Science and the Institute for Data, Systems, and Society at MIT.

Uhler develops machine learning methods for integrating and translating between vastly different data modalities and inferring causal or regulatory relationships from such data. She is particularly interested in using these methods to gain mechanistic insights into the link between genome packing and regulation in health and disease.

Uhler is recognized as a creative and innovative researcher at the intersection of machine learning, statistics, and biology. She has received multiple prestigious career prizes including a Simons Investigator Award, a Sloan Research Fellowship, a Sofja Kovalevskaja Award, and an NSF Career Award.

Uhler holds an M.Sc. in mathematics, a B.Sc. in biology, and an M.Ed., all from the University of Zurich. She obtained her Ph.D. in statistics from UC Berkeley in 2011 and then spent three years as an assistant professor at IST Austria before joining the faculty at MIT.

Rahul Satija, PhD

Dr. Rahul Satija is a Core Faculty Member at the New York Genome Center, with a joint appointment as an Associate Professor at the NYU Center for Genomics and Systems Biology.

Dr. Satija’s group focuses on developing computational and experimental methods to sequence and interpret the molecular contents of a single cell. His group applies single cell genomics to understand the causes and consequences of cell-to-cell variation, with a particular focus on immune regulation and early development.

Dr. Satija holds a BS in Biology and Music from Duke University, and obtained his PhD in Statistics from Oxford University as a Rhodes Scholar. Prior to joining the New York Genome Center, he was a postdoctoral researcher at the BroadInstitute of Harvard and MIT, where he developed new methods for single cell analysis.

Tony Ho, MD

Dr. Tony Ho was Executive Vice President, Head of Research and Development at CRISPR Therapeutics. In a period of 4 years, he built a world class R&D engine and a pipeline of over 10 product candidates. He and his team have brought first CRISPR based therapy CTX001, 3 allogeneic CAR-T (CTX110 (CD19), 120 (BCMA), 130 (CD70)), and the first CRISPR edited pancreatic islet progenitor cells (VCTX210) from research bench to the clinic. Prior to CRISPR Therapeutics, he was SVP and Head of Oncology Integration and Innovation at AstraZeneca and oversaw the development and commercialization of Lynparza and Imfinizi (anti-PD-L1). 10 Phase 3 trials designed under his leadership have now read out positive (Lynparza: SOLO1, SOLO2, SOLO3-1L & PSR Ovarian, OlympiAD-TNBC, POLO-Pancreatic, PAOLA – 1L Ovarian, ProFound 2LmCRC, ; Imfinizi: Pacific- NSCLC, CASPIAN 1L SCLC, Poseidon 1L NSCLC (IO+IO+CHEMO). Tony has successfully repositioned a failed NK3 antagonist for PCOS. Prior to joining AstraZeneca, Tony was the head of Neurology and Ophthalmology at Merck and led the development and launch of Zioptan and several Phase 3 programs including CGRP-RA for migraine, A2a-RA for Parkinson’s disease, prostaglandin for glaucoma, and several early programs in neuropathic pain, stroke, Alzheimer’s disease. Prior to Merck, Tony was the Co-Founder and CSO of Neuronyx, a start-up that developed stem cells for heart failure, immuno-oncology and islet cells. Tony received B.S. in Electrical Engineering at UCLA, and M.D. from Johns Hopkins. He was Assistant Professor at Johns Hopkins specialized in neuropathy and neuromuscular diseases. Tony described and elucidated the pathogenesis of a new disease called “acute motor axonal neuropathy (AMAN)”. He has published widely in several fields with over 80 papers. He is currently Adjunct Associate Professor of Neurology at University of Pennsylvania and Assistant Professor of Neurology at Johns Hopkins University.

Prof. Ido Amit

Ido Amit is a Professor at the Immunology Department at the Weizmann Institute of Science and HHMI International Research Scholar. His lab has led and pioneered the development of single-cell genomics and its application to the characterization of the immune system. His research using these technologies has revolutionized our understanding of the immune system, identifying dozens of new immune subsets. His technologies and discoveries are enabling the development of novel immunotherapy strategies, which he utilized for the development of the next generation of immunotherapy treatments. His international profile as one of the leaders of the immuno-genomics field is demonstrated by numerous impactful papers in leading journals, a large number of excellence prizes, a strong track record of external funding, advisory positions, and company formation.

Jimmie Ye, PhD

Dr. Ye received his bachelor’s degrees in Electrical Engineering and Computer Sciences and Bioengineering from UC Berkeley and a PhD in Systems Biology from UC San Diego.

After a postdoctoral fellowship at the Broad Institute with Dr. Aviv Regev, Dr. Ye started his lab at UCSF five years ago. At UCSF, he is an Associate Professor in the Department of Medicine and is a member of the Institute for Human Genetics, the Bakar Institute for Computational Health Sciences and the Gladstone Institute for Genomic Immunology. He is also an affiliated investigator at the Parker Institute for Cancer Immunotherapy at the Chan Zuckerberg Biohub.

The Ye lab is interested in how the interaction between genetics and environment affect human variation at the level of molecular phenotypes. To study these interactions, the lab couples high-throughput sequencing approaches that measure cellular response under environmental challenges with population genetics where such measurements are collected and analyzed across large patient cohorts. The lab develops novel experimental approaches that enable the large-scale collection of functional genomic data en masse and computational approaches that translate the data into novel biological insights. This approach is used to initially study primary human immune cells in both healthy and diseased patients to understand host pathogen interactions and its role in autoimmunity.

Headquarters

Home

Therapeutics

Our Company